chore: update performance tracking 2026-04-04
This commit is contained in:
github-actions[bot]
parent
1e06895946
commit
42999857af
|
|
@ -1,6 +1,6 @@
|
|||
{
|
||||
"last_updated": "2026-04-04 13:34:53",
|
||||
"total_recommendations": 561,
|
||||
"last_updated": "2026-04-04 13:37:06",
|
||||
"total_recommendations": 565,
|
||||
"recommendations_by_date": {
|
||||
"2026-02-10": [
|
||||
{
|
||||
|
|
@ -13118,6 +13118,84 @@
|
|||
"return_1d": 0.0,
|
||||
"win_1d": false
|
||||
}
|
||||
],
|
||||
"2026-04-04": [
|
||||
{
|
||||
"ticker": "PAGS",
|
||||
"rank": 1,
|
||||
"company_name": "PagSeguro Digital Ltd.",
|
||||
"description": "PagSeguro Digital Ltd. engages in the provision of financial and payment solutions for consumers, entrepreneurs, and small/medium businesses in Brazil.",
|
||||
"strategy_match": "insider_buying",
|
||||
"pipeline": "insider_buying",
|
||||
"final_score": 88,
|
||||
"confidence": 8,
|
||||
"risk_level": "moderate",
|
||||
"reason": "Director Luis Frias executed a massive $4.96M insider purchase, providing a strong fundamental floor for the stock. This is corroborated by highly unusual bullish options flow, highlighted by a staggering 0.021 P/C ratio and heavy call buying at the $14 strike. Technicals are aligning with the accumulation, showing a MACD bullish crossover and price action holding above the 20 EMA and VWAP. The risk/reward is highly favorable given the low valuation (P/E 7.55), though failure to break the 50 SMA at $10.51 could stall momentum.",
|
||||
"entry_price": 10.34000015258789,
|
||||
"discovery_date": "2026-04-04",
|
||||
"status": "open",
|
||||
"current_price": 10.34000015258789,
|
||||
"return_pct": 0.0,
|
||||
"days_held": 0,
|
||||
"last_updated": "2026-04-04"
|
||||
},
|
||||
{
|
||||
"ticker": "ZBIO",
|
||||
"rank": 2,
|
||||
"company_name": "Zenas BioPharma, Inc.",
|
||||
"description": "Zenas BioPharma, Inc. is a clinical-stage biopharma company developing immunology-based therapies.",
|
||||
"strategy_match": "insider_buying",
|
||||
"pipeline": "insider_buying",
|
||||
"final_score": 85,
|
||||
"confidence": 7,
|
||||
"risk_level": "high",
|
||||
"reason": "ZBIO is experiencing aggressive cluster buying, with three insiders\u2014including the CEO ($1.0M) and a 10% owner ($3.0M)\u2014purchasing over $5.5M in shares. This heavy insider accumulation is a massive vote of confidence and directly challenges the elevated short interest of 21.1%. Short-term momentum is accelerating, evidenced by an intraday jump of +6.4% and the price crossing above both the VWAP and 20 EMA. While the setup is primed for a squeeze, the stock's pre-revenue status and high volatility (ATR 9.1%) present substantial fundamental risks.",
|
||||
"entry_price": 21.459999084472656,
|
||||
"discovery_date": "2026-04-04",
|
||||
"status": "open",
|
||||
"current_price": 21.459999084472656,
|
||||
"return_pct": 0.0,
|
||||
"days_held": 0,
|
||||
"last_updated": "2026-04-04"
|
||||
},
|
||||
{
|
||||
"ticker": "PACB",
|
||||
"rank": 3,
|
||||
"company_name": "Pacific Biosciences of California, Inc.",
|
||||
"description": "Pacific Biosciences of California, Inc. designs and manufactures sequencing solutions to resolve genetically complex problems.",
|
||||
"strategy_match": "earnings_play",
|
||||
"pipeline": "earnings_play",
|
||||
"final_score": 70,
|
||||
"confidence": 6,
|
||||
"risk_level": "speculative",
|
||||
"reason": "PACB presents a compelling binary setup heading into its earnings report in three days. The options market is aggressively positioning for an upside move, reflected by an extremely bullish P/C volume ratio of 0.086. Combined with a high short interest of 15.6%, any positive surprise or forward guidance could trigger a violent short squeeze. A recent MACD bullish crossover and an intraday bounce of +3.9% indicate pre-earnings accumulation, though the underlying cash burn and strong macro downtrend pose severe risks if earnings disappoint.",
|
||||
"entry_price": 1.340000033378601,
|
||||
"discovery_date": "2026-04-04",
|
||||
"status": "open",
|
||||
"current_price": 1.340000033378601,
|
||||
"return_pct": 0.0,
|
||||
"days_held": 0,
|
||||
"last_updated": "2026-04-04"
|
||||
},
|
||||
{
|
||||
"ticker": "NNOX",
|
||||
"rank": 4,
|
||||
"company_name": "Nano-X Imaging Ltd.",
|
||||
"description": "Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source and provides teleradiology services.",
|
||||
"strategy_match": "earnings_play",
|
||||
"pipeline": "earnings_play",
|
||||
"final_score": 60,
|
||||
"confidence": 5,
|
||||
"risk_level": "speculative",
|
||||
"reason": "With earnings arriving in just two days, NNOX is flashing contrarian bullish signals driven by options flow and short positioning. The options P/C ratio sits at a heavily skewed 0.241, suggesting speculators are betting on an earnings beat or short squeeze. A short interest of 13.3% provides the fuel for a potential rapid upward rerating. However, the company's operating margin of -413% and high volatility (ATR 6.3%) make this a strictly speculative, binary trade heavily reliant on the upcoming catalyst.",
|
||||
"entry_price": 2.4100000858306885,
|
||||
"discovery_date": "2026-04-04",
|
||||
"status": "open",
|
||||
"current_price": 2.4100000858306885,
|
||||
"return_pct": 0.0,
|
||||
"days_held": 0,
|
||||
"last_updated": "2026-04-04"
|
||||
}
|
||||
]
|
||||
}
|
||||
}
|
||||
|
|
@ -1,5 +1,5 @@
|
|||
{
|
||||
"total_recommendations": 561,
|
||||
"total_recommendations": 565,
|
||||
"by_strategy": {
|
||||
"momentum": {
|
||||
"count": 136,
|
||||
|
|
@ -32,7 +32,7 @@
|
|||
"win_rate_30d": 35.7
|
||||
},
|
||||
"insider_buying": {
|
||||
"count": 163,
|
||||
"count": 165,
|
||||
"wins_1d": 61,
|
||||
"losses_1d": 101,
|
||||
"wins_7d": 71,
|
||||
|
|
@ -62,7 +62,7 @@
|
|||
"win_rate_30d": 30.0
|
||||
},
|
||||
"earnings_play": {
|
||||
"count": 57,
|
||||
"count": 59,
|
||||
"wins_1d": 20,
|
||||
"losses_1d": 37,
|
||||
"wins_7d": 22,
|
||||
|
|
|
|||
Loading…
Reference in New Issue